Phibro Animal Health Corporation (PAHC) Earns Buy Rating from Piper Jaffray Companies

Piper Jaffray Companies reissued their buy rating on shares of Phibro Animal Health Corporation (NASDAQ:PAHC) in a research note published on Friday. Piper Jaffray Companies currently has a $42.00 target price on the stock.

A number of other research firms have also issued reports on PAHC. Bank of America Corporation reissued an underperform rating and set a $33.00 price target on shares of Phibro Animal Health Corporation in a research report on Wednesday, August 23rd. Zacks Investment Research lowered shares of Phibro Animal Health Corporation from a hold rating to a sell rating in a research report on Wednesday, November 8th. ValuEngine lowered shares of Phibro Animal Health Corporation from a buy rating to a hold rating in a research report on Thursday, November 9th. Credit Suisse Group raised their price target on shares of Phibro Animal Health Corporation from $36.00 to $37.00 and gave the stock an outperform rating in a research report on Thursday, August 31st. Finally, BidaskClub lowered shares of Phibro Animal Health Corporation from a strong-buy rating to a buy rating in a research report on Wednesday, August 23rd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of $38.25.

Phibro Animal Health Corporation (NASDAQ PAHC) opened at $34.45 on Friday. The company has a market cap of $1,390.33, a P/E ratio of 22.61, a P/E/G ratio of 4.06 and a beta of 1.35. The company has a debt-to-equity ratio of 1.91, a current ratio of 3.26 and a quick ratio of 1.85. Phibro Animal Health Corporation has a 1 year low of $26.10 and a 1 year high of $40.25.

Phibro Animal Health Corporation (NASDAQ:PAHC) last posted its quarterly earnings results on Monday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.01. Phibro Animal Health Corporation had a net margin of 8.87% and a return on equity of 42.75%. The company had revenue of $193.40 million during the quarter, compared to analyst estimates of $189.89 million. During the same period last year, the firm posted $0.36 EPS. Phibro Animal Health Corporation’s revenue for the quarter was up 2.9% compared to the same quarter last year. research analysts anticipate that Phibro Animal Health Corporation will post 1.57 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://transcriptdaily.com/2017/11/14/phibro-animal-health-corporation-pahc-earns-buy-rating-from-piper-jaffray-companies.html.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 27th. Stockholders of record on Wednesday, December 6th will be issued a dividend of $0.10 per share. This represents a $0.40 annualized dividend and a dividend yield of 1.16%. The ex-dividend date of this dividend is Tuesday, December 5th. Phibro Animal Health Corporation’s dividend payout ratio (DPR) is 23.53%.

In related news, VP Daniel M. Bendheim sold 5,938 shares of Phibro Animal Health Corporation stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $40.04, for a total value of $237,757.52. Following the sale, the vice president now owns 300 shares of the company’s stock, valued at approximately $12,012. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel M. Bendheim sold 4,976 shares of Phibro Animal Health Corporation stock in a transaction on Monday, August 21st. The shares were sold at an average price of $40.01, for a total transaction of $199,089.76. Following the completion of the sale, the vice president now directly owns 4,176 shares in the company, valued at approximately $167,081.76. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 290,705 shares of company stock valued at $10,555,178. Insiders own 51.88% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Morgan Stanley boosted its stake in Phibro Animal Health Corporation by 1.7% during the 1st quarter. Morgan Stanley now owns 172,773 shares of the company’s stock worth $4,855,000 after purchasing an additional 2,868 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in Phibro Animal Health Corporation during the 2nd quarter worth $6,353,000. Sawgrass Asset Management LLC acquired a new stake in Phibro Animal Health Corporation during the 2nd quarter worth $410,000. Sit Investment Associates Inc. boosted its stake in Phibro Animal Health Corporation by 8.8% during the 3rd quarter. Sit Investment Associates Inc. now owns 78,200 shares of the company’s stock worth $2,897,000 after purchasing an additional 6,325 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Phibro Animal Health Corporation by 8.2% during the 1st quarter. Vanguard Group Inc. now owns 1,729,406 shares of the company’s stock worth $48,597,000 after purchasing an additional 130,935 shares during the last quarter. 50.36% of the stock is currently owned by institutional investors.

About Phibro Animal Health Corporation

Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.

Receive News & Ratings for Phibro Animal Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply